Teerlink, John R.; Díaz, Rafael; Felker, G. Michael; McMurray, John J.V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias‐Mendoza, Alexandra; Biering‐Sørensen, Tor; Böhm, Michael; Bonderman, Diana; Cleland, John G.F.; Corbalán, Ramón; Crespo-Leiro, María Generosa; Dahlström, Ulf; Echeverría Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Cándida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin‐ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J.A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E. (Willey Online Library, 2020-09-20)
[Abstract]
Aims
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...